The conformation of the extracellular binding domain of Death Receptor 5 in the presence and absence of the activating ligand TRAIL: A molecular dynamics study

Proteins: Structure, Function and Genetics

Volumn 70, Issue 2, 2008, Pages 333-343

  Wassenaar, Tsjerk A ^a   Quax, Wim J ^a,b   Mark, Alan E ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cytokine; Molecular dynamics; Pre ligand association domain (PLAD); Self association; Simulation; TNF receptor superfamily

Indexed keywords

CYTOKINE RECEPTOR; DEATH RECEPTOR 5; LIGAND; MONOMER; POLYMER; TRIMER; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; MOLECULAR DYNAMICS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; SIMULATION;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; LIGANDS; PROTEIN CONFORMATION; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 37849032983     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.21541     Document Type: Article

References (69)

1. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, Goodwin RG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-682.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-12690.
3. Mariani SM, Matiba B, Armandola EA, Krammer PH. Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells. J Cell Biol 1997;137:221-229.
4. Marsters SA, Pitti RM, Donahue CJ, Ruppert S, Bauer KD, Ashkenazi A. Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr Biol 1996;6:750-752.
5. Lum JJ, Pilon AA, Sanchez-Dardon J, Phenix BN, Kim JE, Mihowich J, Jamison K, Hawley-Foss N, Lynch DH, Badley AD. Induction of cell death in human immunodeficiency virus-infected macrophages and resting memory CD4 T cells by TRAIL/Apo2L. J Virol 2001;75:11128-11136.
6. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JCL, Lynch DH. Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-163.
7. Pan GH, Orourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science 1997;276:111-113.
8. Pan GH, Ni J, Wei YF, Yu GL, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997;277:815-818.
9. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-821.
10. Walczak H, DegliEsposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997;16:5386-5397.
11. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappa B pathway. Immunity 1997;7:821-830.
12. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997;416:329-334.
13. MacFarlane M, Ahmad M, Srinivasula SM, FernandesAlnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997;272:25417-25420.
14. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997;7:693-696.
15. Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, ElDeiry WS. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997;17:141-143.
16. DegliEsposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF, Goodwin RG, Smith CA. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997;186:1165-1170.
17. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997;7:1003-1006.
18. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappa B and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997;7:813-820.
19. Pan GH, Ni J, Yu GL, Wei YF, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998;424:41-45.
20. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998;273:14363-14367.
21. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, RenshawGegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
22. Walczak H, Krammer PH. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp Cell Res 2000;256:58-66.
23. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-1308.
24. Chan FKM, Chun HJ, Zheng LX, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000;288:23512354.
25. Papoff G, Hausler P, Eramo A, Pagano MG, Di Leve G, Signore A, Ruberti G. Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor. J Biol Chem 1999;274:38241-38250.
26. Siegel RM, Frederiksen JK, Zacharias DA, Chan FKM, Johnson M, Lynch D, Tsien RY, Lenardo MJ. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2354-2357.
27. Lee HW, Lee SH, Lee HW, Ryu YW, Kwon MH, Kim YS. Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem Biophys Res Commun 2005;330:1205-1212.
28. Naismith JH, Sprang SR. Modularity in the TNF-receptor family. Trends Biochem Sci 1998;23:74-79.
29. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27:19-26.
30. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563-571.
31. Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY, Screaton GR. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999;6:1048-1053.
32. Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, Lee MS, Oh BH. Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. J Biol Chem 2000;275:31171-31177.
33. McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR, Alber T. Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA 1999;96:8408-8413.
34. Banner DW, Darcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C, Loetscher H, Lesslauer W. Crystal-structure of the soluble human 55 Kd Tnf receptor-human Tnf-Beta complex - implications for Tnf receptor activation. Cell 1993;73:431-445.
35. Jones EY. The tumour necrosis factor receptor family: life or death choices. Curr Opin Struct Biol 2000;10:644-648.
36. Bodmer JL, Meier P, Tschopp J, Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000;275:20632-20637.
37. Ryde U. Molecular-Dynamics Simulations of Alcohol-Dehydrogenase with a 4-Coordinate or 5-Coordinate Catalytic Zinc Ion. Proteins: Struct Funct Genet 1995;21:40-56.
38. Bekker H, van den Berg JP, Wassenaar TA. A method to obtain a near-minimal-volume molecular simulation of a macromolecule, using periodic boundary conditions and rotational constraints. J Comput Chem 2004;25:1037-1046.
39. Amadei A, Chillemi G, Ceruso MA, Grottesi A, Di Nola A. Molecular dynamics simulations with constrained roto-translational motions: theoretical basis and statistical mechanical consistency. J Chem Phys 2000;112:9-23.
40. Wassenaar TA, Mark AE. The effect of box shape on the dynamic properties of proteins simulated under periodic boundary conditions. J Comput Chem 2006;27:316-325.
41. Berendsen HJC, van der Spoel D, van Drunen R. Gromacs - a message-passing parallel molecular-dynamics implementation. Comput Phys Commun 1995;91:43-56.
42. Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 2001;7:306-317.
43. van der Spoel D, van Buuren AR, Apol MEF, Meulenhoff PJ, Tieleman DP, Sijbers ALTM, Hess B, Feenstra KA, Lindahl E, van Drunen R, Berendsen HJC. Gromacs user manual, version 3.1. University of Groningen: Groningen, The Netherlands; 2002.
44. van Gunsteren WF, Billeter SR, Eising AA, Hunenberger PH, Kruger P, Mark AE, Scott WRP, Tironi IG. Biomolecular simulation: GROMOS96 manual and user guide. Zürich: BIOMOS BV; 1996.
45. Schuler LD, Daura X, van Gunsteren WF. An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase. J Comput Chem 2001;22:1205-1218.
46. Berendsen HJC, Postma JPM, van Gunsteren WF, Hermans J. In: Pullman B, editor. Intermolecular forces. Dordrecht: Reidel; 1981. pp 331-342.
47. Tironi IG, Sperb R, Smith PE, van Gunsteren WF. A Generalized reaction field method for molecular-dynamics simulations. J Chem Phys 1995;102:5451-5459.
48. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. Molecular-dynamics with coupling to an external bath. J Chem Phys 1984;81:3684-3690.
49. Miyamoto S, Kollman PA. Settle - an analytical version of the shake and rattle algorithm for rigid water models. J Comput Chem 1992;13:952-962.
50. Hess B, Bekker H, Berendsen HJC, Fraaije J. LINCS: a linear constraint solver for molecular simulations. J Comput Chem 1997;18:1463-1472.
51. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical-integration of cartesian equations of motion of a system with constraints - molecular-dynamics of N-alkanes. J Comput Phys 1977;23:327-341.
52. Eisenhaber F, Lijnzaad P, Argos P, Sander C, Scharf M. The double cubic lattice method - efficient approaches to numerical-integration of surface-area and volume and to dot surface contouring of molecular assemblies. J Comput Chem 1995;16:273-284.
53. Hayward S, Berendsen HJC. Systematic analysis of domain motions in proteins from conformational change: new results on citrate synthase and T4 lysozyme. Proteins: Struct Funct Genet 1998;30:144-154.
54. The MathWorks. MatLab, 6.5. Natick, MA: The MathWorks; 2004.
55. DeLano WL. The Pymol molecular graphics system, 0.99. San Carlos, CA: DeLano Scientific; 2005.
56. Povray Development Core. Persistence of vision raytracer, 3.6. Persistence of Vision Raytracer Pty. Ltd: Williamstown, Victoria, Australia; 2004.
57. Jain T, Jayaram B. An all atom energy based computational protocol for predicting binding affinities of protein-ligand complexes. FEBS Lett 2005;579:6659-6666.
58. Baker BM, Murphy KP. Dissecting the energetics of a protein-protein interaction: the binding of ovomucoid third domain to elastase. J Mol Biol 1997;268:557-569.
59. Eisenberg D, McLachlan AD. Solvation energy in protein folding and binding. Nature 1986;319:199-203.
60. Noskov SY, Lim C. Free energy decomposition of protein-protein interactions. Biophys J 2001;81:737-750.
61. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Eng J Med 1996;334:1717-1725.
62. Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, Smith SO, Constantinescu SN. Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell 2003;12:1239-1250.
63. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, Seeber RM, Monks TA, Eidne KA, Parker MW, Waters MJ. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nature Struct Mol Biol 2005;12:814-821.
64. Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, Laurent G, Latruffe N, Solary E. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene 2004;23:8979-8986.
65. Guo CL, Levine H. A statistical mechanics model for receptor clustering. J Biol Phys 2000;26:219-234.
66. Sulzer B, Perelson AS. Equilibrium binding of multivalent ligands to cells: effects of cell and receptor density. Math Biosci 1996;135:147-185.
67. Cochran AG, Kim PS. Imitation of Escherichia coli aspartate receptor signaling in engineered dimers of the cytoplasmic domain. Science 1996;271:1113-1116.
68. Zhou RH, Huang XH, Margulis CJ, Berne BJ. Hydrophobic collapse in multidomain protein folding. Science 2004;305:1605-1609.
69. Liu P, Huang XH, Zhou RH, Berne BJ. Observation of a dewetting transition in the collapse of the melittin tetramer. Nature 2005;437:159-162.